OptiBiotix Health Past Earnings Performance
Past criteria checks 0/6
OptiBiotix Health has been growing earnings at an average annual rate of 10.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 14.4% per year.
Key information
10.5%
Earnings growth rate
11.1%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 14.4% |
Return on equity | -145.4% |
Net Margin | -1,912.2% |
Last Earnings Update | 30 Jun 2023 |
Revenue & Expenses BreakdownBeta
How OptiBiotix Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 1 | -13 | 2 | 0 |
31 Mar 23 | 1 | -5 | 2 | 0 |
31 Dec 22 | 0 | 3 | 3 | 0 |
30 Sep 22 | 1 | 4 | 2 | 0 |
30 Jun 22 | 1 | 6 | 2 | 0 |
31 Mar 22 | 2 | 6 | 2 | 0 |
31 Dec 21 | 2 | 6 | 2 | 0 |
30 Sep 21 | 2 | 13 | 2 | 0 |
30 Jun 21 | 2 | 21 | 2 | 0 |
31 Mar 21 | 2 | 13 | 2 | 0 |
31 Dec 20 | 2 | 6 | 2 | 0 |
31 Dec 19 | 1 | -2 | 2 | 0 |
31 May 19 | 1 | -2 | 2 | 0 |
28 Feb 19 | 1 | -2 | 2 | 0 |
30 Nov 18 | 1 | -2 | 2 | 0 |
31 Aug 18 | 0 | -2 | 2 | 0 |
31 May 18 | 0 | -2 | 2 | 0 |
28 Feb 18 | 0 | 0 | 2 | 0 |
30 Nov 17 | 0 | 2 | 2 | 0 |
31 Aug 17 | 0 | 2 | 2 | 0 |
31 May 17 | 0 | 2 | 1 | 0 |
28 Feb 17 | 0 | 1 | 1 | 0 |
30 Nov 16 | 0 | -1 | 1 | 0 |
31 Aug 16 | 0 | -1 | 1 | 0 |
31 May 16 | 0 | -1 | 1 | 0 |
29 Feb 16 | 0 | -1 | 1 | 0 |
30 Nov 15 | 0 | -1 | 1 | 0 |
31 Aug 15 | 0 | -1 | 1 | 0 |
31 May 15 | 0 | -1 | 1 | 0 |
28 Feb 15 | 0 | -1 | 1 | 0 |
30 Nov 14 | 0 | -1 | 0 | 0 |
31 May 14 | 0 | 0 | 0 | 0 |
28 Feb 14 | 0 | -1 | 0 | 0 |
Quality Earnings: OPTI is currently unprofitable.
Growing Profit Margin: OPTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPTI is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.
Accelerating Growth: Unable to compare OPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: OPTI has a negative Return on Equity (-145.44%), as it is currently unprofitable.